Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $424.76 million. The enterprise value is $93.35 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 59.08 million shares outstanding. The number of shares has increased by 18.23% in one year.
| Current Share Class | 59.08M |
| Shares Outstanding | 59.08M |
| Shares Change (YoY) | +18.23% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.98% |
| Owned by Institutions (%) | 80.17% |
| Float | 38.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.45, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.45 |
| Quick Ratio | 10.15 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.18% and return on invested capital (ROIC) is -27.87%.
| Return on Equity (ROE) | -40.18% |
| Return on Assets (ROA) | -26.53% |
| Return on Invested Capital (ROIC) | -27.87% |
| Return on Capital Employed (ROCE) | -53.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.95M |
| Employee Count | 111 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CGEM has paid $117,000 in taxes.
| Income Tax | 117,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.37% in the last 52 weeks. The beta is -0.07, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -56.37% |
| 50-Day Moving Average | 7.05 |
| 200-Day Moving Average | 7.99 |
| Relative Strength Index (RSI) | 46.39 |
| Average Volume (20 Days) | 1,064,685 |
Short Selling Information
The latest short interest is 6.63 million, so 11.22% of the outstanding shares have been sold short.
| Short Interest | 6.63M |
| Short Previous Month | 6.10M |
| Short % of Shares Out | 11.22% |
| Short % of Float | 17.34% |
| Short Ratio (days to cover) | 5.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -241.44M |
| Pretax Income | -216.70M |
| Net Income | -216.81M |
| EBITDA | -241.13M |
| EBIT | -241.44M |
| Earnings Per Share (EPS) | -$3.68 |
Full Income Statement Balance Sheet
The company has $332.60 million in cash and $1.19 million in debt, giving a net cash position of $331.41 million or $5.61 per share.
| Cash & Cash Equivalents | 332.60M |
| Total Debt | 1.19M |
| Net Cash | 331.41M |
| Net Cash Per Share | $5.61 |
| Equity (Book Value) | 451.37M |
| Book Value Per Share | 7.64 |
| Working Capital | 309.48M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$174.27 million and capital expenditures -$38,000, giving a free cash flow of -$174.31 million.
| Operating Cash Flow | -174.27M |
| Capital Expenditures | -38,000 |
| Free Cash Flow | -174.31M |
| FCF Per Share | -$2.95 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGEM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.23% |
| Shareholder Yield | -18.23% |
| Earnings Yield | -51.04% |
| FCF Yield | -41.04% |
Analyst Forecast
The average price target for CGEM is $26.00, which is 261.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.00 |
| Price Target Difference | 261.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 4.81% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |